Researches on the Chemotherapy of Malaria: II. The Chemical Approach (1947)

Peer-Reviewed Study · Curd FHS (Research Laboratories, Imperial Chemical Industries Ltd, Blackley, Manchester) · March 1947

Curd FHS (Research Laboratories, 1947-03: A 1947 ICI chemist's account stating that the German synthetic-antimalarial programme took methylene blue, shown antimalarial by Ehrlich and Guttmann in 1891, as its starting point, and tracing the line through pamaquin (too toxic) to mepacrine and then chloroquine.

Their starting point was methylene blue (I.) which had been shown by Ehrlich and Guttmann as early as 1891 to possess some antimalarial action.

74

Curd FHS (Research Laboratories, 1947-03: A 1947 ICI chemist's account stating that the German synthetic-antimalarial programme took methylene blue, shown antimalarial by Ehrlich and Guttmann in 1891, as its starting point, and tracing the line through pamaquin (too toxic) to mepacrine and then chloroquine. C5 , Curd FHS. Researches on the chemotherapy of malaria: II. The chemical approach. Glasgow Med J 1947;28(3):73-79; PMID 20292989; PMCID PMC5969664. English, United Kingdom (paper read before the Glasgow Royal Medico-Chirurgical Society, 29 November 1946). Excerpt sliced from the Europe PMC fullTextXML; the OCR carriage-return entities at line ends were removed and whitespace normalised, wording unchanged. The same article supplies the reasons in sequence, verbatim: 'Pamaquin was not a very good drug for the purpose for which it was devised, i.e., as a synthetic substitute for quinine. It was too toxic and influenced clinical malaria only in toxic or just sub toxic doses, and so the search went on' , then mepacrine (Mauss & Mietzsch, 1933) and, for the American line, 'the compound (VI.) which they have introduced under the name Chloroquine'. Historical review, not a study: no N, dose, funder or conflict statement; the author was an ICI employee, disclosed in the byline. Fetch route: Europe PMC REST fullTextXML. Study type: review.